Table 6.
Susceptibility of ibalizumab-resistant virus to BMS-626529a
| HIV-1 entry inhibitor | Mean EC50 (nM) ± SD for NL4-3 |
Clinical envelope |
||||||
|---|---|---|---|---|---|---|---|---|
| Wild type | NL4-3(S162N,A605T/A) | Mean EC50 (nM) ± SD |
Mean MPI ± SD |
|||||
| Ibal-S (2 PNGSs) | Ibal-R | Ibal-R M426L | Ibal-S | Ibal-R | Ibal-R M426L | |||
| BMS-626529 | 0.12 ± 0.0 | 0.082 ± 0.081 | 11.4 ± 2.9 | 3.9 ± 0.8 | 455 ± 87 | 101.7 ± 0.03 | 101.2 ± 0.0 | 100.7 ± 0.5 |
| Ibalizumab | 1.33 ± 0.1 | >995 | 0.45 ± 0.1 | 3.2 ± 0.1 | 5.5 ± 3.2 | 102.6 ± 0.6 | 80.0 ± 12.0 | 83.2 ± 1.8 |
a
Ibal-R, ibalizumab-resistant clinical envelope; ibal-S, ibalizumab-sensitive clinical envelope; MPI, maximum percent inhibition; PNGSs, potential N-linked glycosylation sites in V5. Mean values of two independent experiments are shown.